LUMO – lumos pharma, inc. (US:NASDAQ)
Stock Stats
News
Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201's Unique Pulsatile Mechanism of Action [Yahoo! Finance]
Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201’s Unique Pulsatile Mechanism of Action
Lumos Pharma, Inc. (NASDAQ: LUMO) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $4.25 price target on the stock.
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Lumos Pharma Inc. – LUMO
Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62n? Annual ESPE Meeting 2024
Form SC 14D9 LUMOS PHARMA, INC. Filed by: LUMOS PHARMA, INC.
Form SC TO-T LUMOS PHARMA, INC. Filed by: Double Point Ventures LLC
Form SC 13G LUMOS PHARMA, INC. Filed by: Private Advisor Group, LLC
Form 10-Q LUMOS PHARMA, INC. For: Sep 30
Form SCHEDULE 13G/A LUMOS PHARMA, INC. Filed by: WELLS FARGO & COMPANY/MN
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.